secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001193125-26-166987
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M
--------------------------------------------------------------------------------

- Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.
- Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.
- Tiered high single-digit royalties on net sales in the Territory.
- Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.
- Effectiveness conditional on Amoytop shareholder approval within 45 days of signing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/d50981d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-166987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer